# A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

> **NCT01999972** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** axitinib
- **DRUG:** crizotinib
- **DRUG:** axitinib
- **DRUG:** crizotinib
- **DRUG:** axitinib
- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT01999972
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-26
- **Primary completion:** 2017-02-22
- **Final completion:** 2019-09-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01999972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01999972, "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01999972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*